Categories
SOUTH ASIA

Covaxin trial data: Bharat Biotech vaccine shows 77.8% overall efficacy, 65% against Delta variant – The Economic Times Video [Video]

Hyderabad-based Bharat Biotech has just published the trial data for its COVID-19 vaccine, Covaxin, which claims the India-made vaccine to be 77.8% effective against the coronavirus. The vaccine was found to have 93% efficacy against severe cases of COVID-19 and 63% efficacy against asymptomatic transmission. Trial data also indicated that the vaccine was effective against the Delta variant of the virus. “BBV152 conferred 65.2% protection against the SARS CoV 2 Variant of Concern, B.1.617.2 (Delta),” the release from Bharat Biotech said.

Categories
CENTRAL & SOUTH AMERICA

Brazil top prosecutor to investigate Bolsonaro over Covid-19 vaccine deal • FRANCE 24 English [Video]

#Brazil’s top prosecutor agreed on Friday to request an #investigation of President Jair #Bolsonaro for dereliction of duty in the process of procuring an Indian Covid-19 vaccine. The president has been caught up in allegations of irregularities surrounding the 1.6 billion reais ($316 million) contract signed in February for 20 million doses with a Brazilian intermediary for the vaccine’s maker, Bharat Biotech.The government suspended the contract on Tuesday after a Senate commission raised suspicions of overpricing and corruption. FRANCE 24’s Tim Vickery for the latest.Subscribe to France 24 now:http://f24.my/youtubeENFRANCE 24 live news stream: all the latest news 24/7http://f24.my/YTliveENVisit our website:http://www.france24.comSubscribe to our YouTube channel:http://f24.my/youtubeENLike us on Facebook:https://www.facebook.com/FRANCE24.EnglishFollow us on Twitter:https://twitter.com/France24_en

Categories
SOUTH ASIA

covaxin: India’s Covaxin effectively neutralises Delta and Alpha variants of coronavirus: Top US health institute – The Economic Times Video [Video]

The National Institute of Health (NIH) in the United States has found that Bharat Biotech’s COVAXIN vaccine generates antibodies that effectively neutralize both Alpha and Delta variants of COVID-19. The top health research institute said that an adjuvant developed with funding from the NIH has contributed to the success of the “highly efficacious” COVAXIN COVID-19 vaccine, which roughly 25 million people have received to date in India and elsewhere.

Categories
SOUTH ASIA

Bharat Biotech submits phase 3 trial data of COVAXIN vaccine to WHO for approval – The Economic Times Video [Video]

On Wednesday, India’s indigenous COVID vaccine ‘Covaxin’ manufacturer Bharat Biotech has submitted its phase-3 clinical trial results to the World Health Organization (WHO) for clearance. Hyderabad-based Bharat Biotech’s pre-submission meeting has been scheduled on June 23 for evaluation of the WHO’s Emergency Use Listing (EUL) of its indigenous COVID-19 vaccine Covaxin.

Categories
SOUTH ASIA

Bharat Biotechs ‘Covaxin’ gets DCGI nod for phase 2, 3 clinical trials on children aged 2 to 18 years – The Economic Times Video [Video]

The Drugs Controller General of India (DCGI) on Thursday approved Phase 2 and 3 clinical trial of Bharat Biotech’s COVAXIN vaccine in the age group of 2 to 18 years, informed the Ministry of Health and Family Welfare. Bharat Biotech will conduct trials in 525 healthy volunteers. “In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28,” it said.

Categories
SOUTH ASIA

Bharat Biotechs ‘Covaxin’ gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds – The Economic Times Video [Video]

Subject Expert Committee (SEC) gave nod to Bharat Biotechs Covaxin for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the Covaxin is being used in adults. Covaxin is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.